Welcome to our dedicated page for Strata Critical Medical SEC filings (Ticker: BLDE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Strata Critical Medical's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Strata Critical Medical's regulatory disclosures and financial reporting.
CFO William A. Heyburn reported three transactions in Blade Air Mobility (BLDE) stock. On 08/01/2025 he received 139,286 Class A shares after the Compensation Committee certified that 2024 performance targets tied to previously granted PSUs had been achieved. To satisfy related tax obligations, the company withheld 76,177 shares at $3.99.
Following the vesting, Heyburn beneficially owned 1,463,940 shares. On 08/04/2025, acting under a pre-arranged Rule 10b5-1 plan dated 11/25/2024, he sold 46,918 shares at a weighted-average price of $4.94-$4.96, trimming his stake to 1,340,845 shares. The sale represents roughly 3 % of his current holdings and generated about $232k in gross proceeds. Net of all reported moves, Heyburn’s ownership increased by approximately 16 k shares, or +1 %.
No options or other derivative securities were transacted, and no additional insider participants were listed. Overall, the filing reflects routine equity compensation vesting combined with a modest, pre-scheduled liquidity sale, leaving the CFO with a substantial position aligned with shareholders.
Blade Air Mobility (NASDAQ: BLDE) Q2 2025 10-Q highlights
- Revenue rose 4% YoY to $70.8 m; Medical segment up 18% to $45.1 m, offsetting a 13% Passenger decline to $25.7 m.
- Cost discipline: Total operating expenses fell 5% to $75.8 m, driven by a 20% reduction in G&A and 32% lower selling & marketing spend.
- Profitability improving: Operating loss narrowed to $(5.0) m from $(12.1) m; net loss trimmed to $(3.7) m (-$0.05/sh) versus $(11.3) m (-$0.15/sh) prior-year.
- Segment Adjusted EBITDA grew 34% to $8.4 m; Medical contributed $6.0 m.
- Liquidity: Cash & equivalents $58.8 m plus $54.7 m short-term Treasuries; operating cash burn cut to $3.3 m (vs $7.1 m).
- Balance sheet: Warrant liability marked down to $3.0 m (from $5.8 m); goodwill now $44.3 m after organ-transport acquisitions.
- Share count: 81.7 m shares outstanding, up 2.3 m YTD due to equity compensation; stock-based comp $9.6 m YTD.
- Subsequent event: 1 Aug 25 agreement to sell Passenger business to Joby Aviation for up to $125 m ($90 m at close, $35 m earn-out, cash or JOBY stock). Transaction expected to be treated as discontinued operations.
- Guidance: none provided; management notes seasonality with stronger Q2–Q3 passenger demand.
Key takeaways: Blade is pivoting toward its higher-margin Medical segment while monetizing the Passenger operation. Liquidity remains solid and losses are shrinking, but execution risk on the Joby deal and continued passenger softness warrant monitoring.